Search

Displaying results 1081 - 1090 of 3015 in total
  1. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    The enzyme is a homotetramer consisted of 4 monomers with 629 amino acids, and holds the same amino acid sequence as human beta-glucuronidase (GUS) [FDA Label]. … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.

  2. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy [A34322].

  3. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  4. Drug

    Unoprostone

    go.drugbank.com/drugs/DB06826
    ApprovedWithdrawn

    Unoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate....

  5. Drug

    Imiquimod

    go.drugbank.com/drugs/DB00724
    ApprovedInvestigational

    Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.

  6. Drug

    Vinblastine

    go.drugbank.com/drugs/DB00570
    ApprovedInvestigational

    (Merck, 11th ed.)

  7. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  8. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.

  9. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  10. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    [T50] It was developed by E.